According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.92496. At the end of 2023 the company had a P/S ratio of 7.26.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.26 | -40.49% |
2022 | 12.2 | 9.13% |
2021 | 11.2 | -55.15% |
2020 | 24.9 | -2.22% |
2019 | 25.5 | -1.12% |
2018 | 25.8 | 10.75% |
2017 | 23.3 | -91.58% |
2016 | 276 | -80.34% |
2015 | > 1000 | 2193.16% |
2014 | 61.3 | 13.28% |
2013 | 54.1 | 146.82% |
2012 | 21.9 | 918.16% |
2011 | 2.15 | -73.42% |
2010 | 8.10 | -11.73% |
2009 | 9.17 | 316.41% |
2008 | 2.20 | -73.37% |
2007 | 8.27 | -99.44% |
2006 | > 1000 | 3874.02% |
2005 | 36.9 | -81.29% |
2004 | 197 | 36.42% |
2003 | 145 | -8.87% |
2002 | 159 | -55.81% |
2001 | 359 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | 3.08 | -65.50% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | 2.78 | -68.82% | ๐บ๐ธ USA |
Novavax NVAX | 2.74 | -69.30% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | 9.31 | 4.28% | ๐บ๐ธ USA |
Insmed INSM | 12.1 | 36.01% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | 3.96 | -55.62% | ๐บ๐ธ USA |
Avidity Biosciences RNA | 295 | 3,207.73% | ๐บ๐ธ USA |